Cargando…
Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy
Treatment of pediatric pulmonary hypertension (PH) with IV prostanoids has greatly improved outcomes but requires a central line, posing inherent infection risk. This study examines the types of infections, infection rates, and importantly the effect of line management strategies on reinfection in c...
Autores principales: | McCarthy, Elisa K., Ogawa, Michelle T., Hopper, Rachel K., Feinstein, Jeffrey A., Gans, Hayley A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826011/ https://www.ncbi.nlm.nih.gov/pubmed/29309237 http://dx.doi.org/10.1177/2045893218754886 |
Ejemplares similares
-
Reported Sildenafil Side Effects in Pediatric Pulmonary Hypertension Patients
por: Siehr, Stephanie L., et al.
Publicado: (2015) -
Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015) -
Complex Role for E‐Prostanoid 4 Receptors in Hypertension
por: Herrera, Marcela, et al.
Publicado: (2019) -
Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension
por: Pan, Irene Z., et al.
Publicado: (2020) -
Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension
por: Speich, Rudolf, et al.
Publicado: (2013)